Company profile MTNB
There is not enough data for Matinas BioPharma Holdings (Biotechnology)lipid nanocrystal technology to provide analysis
There is not enough data for Matinas BioPharma Holdings (Biotechnology)lipid nanocrystal technology to provide correlation calculation
There is not enough data for Matinas BioPharma Holdings (Biotechnology)lipid nanocrystal technology to provide analysis
After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0. LYPDISO expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 139 | 15 -89.2% QoQ | 16 6.7% QoQ | 94 487.5% QoQ |
| 2020 | 37 -73.4% YoY -60.6% QoQ | 49 226.7% YoY 32.4% QoQ | 54 237.5% YoY 10.2% QoQ | 65 -30.9% YoY 20.4% QoQ |
| 2021 | 62 67.6% YoY -4.6% QoQ | 16 -67.3% YoY -74.2% QoQ | 56 3.7% YoY 250.0% QoQ | 120 84.6% YoY 114.3% QoQ |
| 2022 | 92 48.4% YoY -23.3% QoQ | 32 100.0% YoY -65.2% QoQ | 17 -69.6% YoY -46.9% QoQ | 120 0.0% YoY 605.9% QoQ |
| 2023 | 27 -70.7% YoY -77.5% QoQ | 97 203.1% YoY 259.3% QoQ | 98 476.5% YoY 1.0% QoQ | 62 -48.3% YoY -36.7% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of LYPDISO was 4.88 per week. The last year interest of LYPDISO compared to the last 5 years has changed by 6.76%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -6.29%.
There is not enough data for prescription omega-3 fatty acid to provide analysis
There is not enough data for prescription omega-3 fatty acid to provide correlation calculation
There is not enough data for prescription omega-3 fatty acid to provide analysis
After 38 days of this quarter the interest is at 242.0. Based on that we can calculate that during remaining 53 days it will total up to 580.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 389 | 519 33.4% QoQ | 403 -22.4% QoQ | 459 13.9% QoQ |
| 2020 | 526 35.2% YoY 14.6% QoQ | 537 3.5% YoY 2.1% QoQ | 478 18.6% YoY -11.0% QoQ | 561 22.2% YoY 17.4% QoQ |
| 2021 | 548 4.2% YoY -2.3% QoQ | 529 -1.5% YoY -3.5% QoQ | 369 -22.8% YoY -30.2% QoQ | 489 -12.8% YoY 32.5% QoQ |
| 2022 | 669 22.1% YoY 36.8% QoQ | 802 51.6% YoY 19.9% QoQ | 552 49.6% YoY -31.2% QoQ | 782 59.9% YoY 41.7% QoQ |
| 2023 | 782 16.9% YoY 0.0% QoQ | 869 8.4% YoY 11.1% QoQ | 589 6.7% YoY -32.2% QoQ | 876 12.0% YoY 48.7% QoQ |
| 2024 | 242 -69.1% YoY -72.4% QoQ | - | - | - |
The average 5 years interest of cardiovascular treatment was 46.04 per week. The last year interest of cardiovascular treatment compared to the last 5 years has changed by 30.04%. The interest for cardiovascular treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 58.68%.
After 38 days of this quarter the interest is at 147.0. Based on that we can calculate that during remaining 53 days it will total up to 352.0. metabolic conditions expected interest is significantly lower compared to previous quarter (-53.3%) and same quarter last year (-40.6%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 197 | 206 4.6% QoQ | 251 21.8% QoQ | 253 0.8% QoQ |
| 2020 | 368 86.8% YoY 45.5% QoQ | 351 70.4% YoY -4.6% QoQ | 308 22.7% YoY -12.3% QoQ | 480 89.7% YoY 55.8% QoQ |
| 2021 | 393 6.8% YoY -18.1% QoQ | 353 0.6% YoY -10.2% QoQ | 294 -4.5% YoY -16.7% QoQ | 440 -8.3% YoY 49.7% QoQ |
| 2022 | 533 35.6% YoY 21.1% QoQ | 476 34.8% YoY -10.7% QoQ | 286 -2.7% YoY -39.9% QoQ | 640 45.5% YoY 123.8% QoQ |
| 2023 | 593 11.3% YoY -7.3% QoQ | 522 9.7% YoY -12.0% QoQ | 410 43.4% YoY -21.5% QoQ | 753 17.7% YoY 83.7% QoQ |
| 2024 | 147 -75.2% YoY -80.5% QoQ | - | - | - |
The average 5 years interest of metabolic conditions was 31.75 per week. The last year interest of metabolic conditions compared to the last 5 years has changed by 37.86%. The interest for metabolic conditions is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 114.77%.
There is not enough data for MAT2203 to provide analysis
There is not enough data for MAT2203 to provide correlation calculation
There is not enough data for MAT2203 to provide analysis
There is not enough data for oral formulation of amphotericin B to provide analysis
There is not enough data for oral formulation of amphotericin B to provide correlation calculation
There is not enough data for oral formulation of amphotericin B to provide analysis
After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0. Phase II clinical trials expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 107 | 70 -34.6% QoQ | 143 104.3% QoQ | 98 -31.5% QoQ |
| 2020 | 47 -56.1% YoY -52.0% QoQ | 204 191.4% YoY 334.0% QoQ | 94 -34.3% YoY -53.9% QoQ | 159 62.2% YoY 69.1% QoQ |
| 2021 | 59 25.5% YoY -62.9% QoQ | 68 -66.7% YoY 15.3% QoQ | 56 -40.4% YoY -17.6% QoQ | 227 42.8% YoY 305.4% QoQ |
| 2022 | 128 116.9% YoY -43.6% QoQ | 53 -22.1% YoY -58.6% QoQ | 190 239.3% YoY 258.5% QoQ | 129 -43.2% YoY -32.1% QoQ |
| 2023 | 64 -50.0% YoY -50.4% QoQ | 54 1.9% YoY -15.6% QoQ | 69 -63.7% YoY 27.8% QoQ | 73 -43.4% YoY 5.8% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Phase II clinical trials was 8.05 per week. The last year interest of Phase II clinical trials compared to the last 5 years has changed by -48.7%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -48.63%.
After 39 days of this quarter the interest is at 34.0. Based on that we can calculate that during remaining 52 days it will total up to 79.0. invasive fungal infections expected interest is significantly higher compared to previous quarter (+64.6%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 52 | 272 423.1% QoQ | 188 -30.9% QoQ | 76 -59.6% QoQ |
| 2020 | 122 134.6% YoY 60.5% QoQ | 94 -65.4% YoY -23.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 192 152.6% YoY inf% QoQ |
| 2021 | 217 77.9% YoY 13.0% QoQ | 102 8.5% YoY -53.0% QoQ | 235 inf% YoY 130.4% QoQ | 78 -59.4% YoY -66.8% QoQ |
| 2022 | 143 -34.1% YoY 83.3% QoQ | 88 -13.7% YoY -38.5% QoQ | 112 -52.3% YoY 27.3% QoQ | 173 121.8% YoY 54.5% QoQ |
| 2023 | 97 -32.2% YoY -43.9% QoQ | 248 181.8% YoY 155.7% QoQ | 253 125.9% YoY 2.0% QoQ | 48 -72.3% YoY -81.0% QoQ |
| 2024 | 34 -64.9% YoY -29.2% QoQ | - | - | - |
The average 5 years interest of invasive fungal infections was 10.82 per week. The last year interest of invasive fungal infections compared to the last 5 years has changed by 8.04%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 0.17%.
After 38 days of this quarter the interest is at 81.0. Based on that we can calculate that during remaining 53 days it will total up to 194.0. immunosuppressive therapy expected interest is significantly lower compared to previous quarter (-53.9%) and same quarter last year (-50.4%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 243 | 193 -20.6% QoQ | 199 3.1% QoQ | 160 -19.6% QoQ |
| 2020 | 382 57.2% YoY 138.8% QoQ | 298 54.4% YoY -22.0% QoQ | 301 51.3% YoY 1.0% QoQ | 282 76.2% YoY -6.3% QoQ |
| 2021 | 273 -28.5% YoY -3.2% QoQ | 277 -7.0% YoY 1.5% QoQ | 440 46.2% YoY 58.8% QoQ | 359 27.3% YoY -18.4% QoQ |
| 2022 | 396 45.1% YoY 10.3% QoQ | 220 -20.6% YoY -44.4% QoQ | 232 -47.3% YoY 5.5% QoQ | 254 -29.2% YoY 9.5% QoQ |
| 2023 | 391 -1.3% YoY 53.9% QoQ | 380 72.7% YoY -2.8% QoQ | 362 56.0% YoY -4.7% QoQ | 421 65.7% YoY 16.3% QoQ |
| 2024 | 81 -79.3% YoY -80.8% QoQ | - | - | - |
The average 5 years interest of immunosuppressive therapy was 23.63 per week. The last year interest of immunosuppressive therapy compared to the last 5 years has changed by 21.84%. The interest for immunosuppressive therapy is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 74.27%.
There is not enough data for MAT2501 to provide analysis
There is not enough data for MAT2501 to provide correlation calculation
There is not enough data for MAT2501 to provide analysis
There is not enough data for broad-spectrum aminoglycoside antibiotic to provide analysis
There is not enough data for broad-spectrum aminoglycoside antibiotic to provide correlation calculation
There is not enough data for broad-spectrum aminoglycoside antibiotic to provide analysis
After 38 days of this quarter the interest is at 274.0. Based on that we can calculate that during remaining 53 days it will total up to 656.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 485 | 911 87.8% QoQ | 889 -2.4% QoQ | 765 -13.9% QoQ |
| 2020 | 770 58.8% YoY 0.7% QoQ | 624 -31.5% YoY -19.0% QoQ | 832 -6.4% YoY 33.3% QoQ | 618 -19.2% YoY -25.7% QoQ |
| 2021 | 717 -6.9% YoY 16.0% QoQ | 805 29.0% YoY 12.3% QoQ | 761 -8.5% YoY -5.5% QoQ | 797 29.0% YoY 4.7% QoQ |
| 2022 | 752 4.9% YoY -5.6% QoQ | 781 -3.0% YoY 3.9% QoQ | 841 10.5% YoY 7.7% QoQ | 868 8.9% YoY 3.2% QoQ |
| 2023 | 870 15.7% YoY 0.2% QoQ | 880 12.7% YoY 1.1% QoQ | 874 3.9% YoY -0.7% QoQ | 977 12.6% YoY 11.8% QoQ |
| 2024 | 274 -68.5% YoY -72.0% QoQ | - | - | - |
The average 5 years interest of amikacin was 61.89 per week. The last year interest of amikacin compared to the last 5 years has changed by 9.31%. The interest for amikacin is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by 4.48%.
There is not enough data for multidrug-resistant bacteria to provide analysis
There is not enough data for multidrug-resistant bacteria to provide correlation calculation
There is not enough data for multidrug-resistant bacteria to provide analysis
There is not enough data for non-tuberculous mycobacterium infections to provide analysis
There is not enough data for non-tuberculous mycobacterium infections to provide correlation calculation
There is not enough data for non-tuberculous mycobacterium infections to provide analysis
There is not enough data for Gilead's antiviral remdesivir to provide analysis
There is not enough data for Gilead's antiviral remdesivir to provide correlation calculation
There is not enough data for Gilead's antiviral remdesivir to provide analysis
There is not enough data for National Institute of Allergy and Infectious Diseases collaboration to provide analysis
There is not enough data for National Institute of Allergy and Infectious Diseases collaboration to provide correlation calculation
There is not enough data for National Institute of Allergy and Infectious Diseases collaboration to provide analysis
There is not enough data for Genentech feasibility collaboration to provide analysis
There is not enough data for Genentech feasibility collaboration to provide correlation calculation
There is not enough data for Genentech feasibility collaboration to provide analysis